中信证券股份有限公司 关于辽宁成大生物股份有限公司 部分募投项目延期、调整内部投资结构并向全资子公司增 资以实施新增募投子项目的核查意见 中信证券股份有限公司（以下简称"保荐机构"或"中信证券"）作为辽宁成大 生物股份有限公司（以下简称"成大生物"或"公司"）首次公开发行股票并在科创 板上市的持续督导保荐机构，根据《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》《上市公司募集资金监管规则》等有关规定，对公司 部分募投项目延期、调整内部投资结构并向全资子公司增资以实施新增募投子项 目的事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意辽宁成大生物股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕3019 号），公司首次公开发 行人民币普通股（A）股 4,165 万股，每股发行价格为 110.00 元，募集资金总额 为人民币 458,150.00 万元；扣除各项发行费用后实际募集资金净额为人民币 434,137.94 万元。其中募投项目拟投入资金 204,000.00 万元，超募资金 230,137.94 万元。上述募集资金已经容诚会 ...

本次事项影响：本次部分募投项目的延期、内部投资结构调整并向全资 子公司增资以实施新增募投子项目相关事项，不会对公司当前及未来的生产经营 产生重大不利影响，亦不存在损害公司及全体股东利益的情形。 一、本次部分募投项目延期、调整内部投资结构并向全资子公司增资以实 施新增募投子项目的概述 （一）募集资金基本情况 证券代码：688739 证券简称：成大生物 公告编号：2025-057 辽宁成大生物股份有限公司 关于部分募投项目延期、调整内部投资结构并向全资子公司 增资以实施新增募投子项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 部分募投项目内部投资结构调整并向全资子公司增资以实施新增募投 子项目情况：为契合公司战略发展布局，积极顺应行业市场动态变化，经审慎论 证与评估，辽宁成大生物股份有限公司（以下简称"公司"）拟对"人用疫苗研 发项目"的内部投资结构进行优化调整。公司决定终止 5 个研发子项目，并将上 述子项目未使用的募集资金统筹调配至其他存续及新增子项目"高价次肺炎球菌 多糖结合疫苗"和"流感病毒裂解 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：致同会计师事务所（特殊普通合伙）（以下 简称"致同所"） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 辽宁成大生物股份有限公司 关于续聘会计师事务所的公告 证券代码：688739 证券简称：成大生物 公告编号：2025-058 统一社会信用代码：91110105592343655N 机构类型：特殊普通合伙 企业注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 成立日期：致同会计师事务所（特殊普通合伙）前身是成立于 1981 年的北 京会计师事务所，2011 年 12 月 22 日经北京市财政局批准转制为特殊普通合伙， 2012 年更名为致同会计师事务所（特殊普通合伙） 执业证书颁发单位及序号：北京市财政局 NO.0014469 经营范围：审计企业会计报表，出具审计报告；验证企业资本，出具验资报 告；办理企业合并、分立、清算事宜中的审计业务，出具有关报告；基本建设年 度财务决算审计；代理记 ...

证券代码：688739 证券简称：成大生物 公告编号：2025-059 辽宁成大生物股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 （二） 股东会召集人：董事会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 12 月 23 日 9 点 30 分 股东会召开日期：2025年12月23日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》 等有关规定执行。 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 召开地点：辽宁省沈阳市浑南区新放街 1 号 公司会议室 （五） 网络投票的系统、起止日期和投票时间 ...

Core Insights - The biopharmaceutical sector is one of the fastest-growing areas in the pharmaceutical industry, driven by an aging population and increased public health awareness [1][5] - China's biopharmaceutical market is projected to grow from CNY 312 billion in 2019 to CNY 587.1 billion in 2024, and is expected to reach CNY 675.2 billion by 2025, with a potential to hit CNY 1.149 trillion in the next five years [1][5][6] - Innovation remains the core driver of growth in the biopharmaceutical industry, which is capital-intensive and requires significant R&D investment [1][6] Industry Definition and Classification - Biopharmaceuticals are medical products manufactured using biological methods, aimed at replicating the activity of natural substances [2][4] - They can be categorized into vaccines, blood products, biopharmaceutical drugs, diagnostic reagents, and others, with further subdivisions based on source or mechanism of action [2] Current Industry Status - The global biopharmaceutical market is expected to grow from USD 286.4 billion in 2019 to USD 461.6 billion in 2024, with the original biopharmaceutical market projected to increase from USD 268.9 billion to USD 427.9 billion in the same period [5] - China plays a significant role in the global biopharmaceutical market, with rapid growth driven by favorable policies, increased R&D investment, and advancements in biotechnology [5][6] Industry Development Environment - Policies - The Chinese government has implemented various laws and policies to encourage biopharmaceutical R&D, including the Drug Registration Management Measures and regulations for clinical research and application of biomedical technologies [7] Competitive Landscape - The biopharmaceutical sector is recognized as a "new frontier" in the pharmaceutical industry, with major global players actively entering the market [9] - Key companies in China's biopharmaceutical industry include WuXi AppTec, Hengrui Medicine, ZhiFei Biological, BeiGene, and others, with a competitive landscape characterized by differentiated strategies [9] Future Development Trends - Market demand for biopharmaceuticals is expected to continue growing, supported by policy backing, technological advancements, and increased health awareness [10] - Domestic companies are transitioning from biosimilars to First-in-Class drugs, with examples like Hengrui Medicine's ADC drug showing superior efficacy [10][11] - Personalized medicine based on genetic testing is anticipated to become a trend, with increasing international recognition of Chinese innovative drugs [11]

Core Insights - Chengda Biotech is developing a biotechnology product research and production base, which is planned in two phases [1] - The first phase includes the production workshop for a 15-valent HPV vaccine, while the second phase will consist of standardized biological product facilities [1] - The 15-valent HPV vaccine is currently in Phase II clinical trials, and the progress of vaccine development and project construction is subject to various uncertainties [1] Summary by Categories - **Project Development** - The biotechnology product research and production base is structured in two phases [1] - Phase one includes facilities for the 15-valent HPV vaccine production [1] - Phase two will focus on standardized biological product manufacturing [1] - **Vaccine Development Status** - The 15-valent HPV vaccine is in Phase II clinical trials [1] - The approval process for the vaccine and project construction faces multiple influencing factors, leading to uncertainties [1] - The company commits to timely disclosures regarding any significant updates [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688739 证券简称：成大生物 公告编号：2025-056 辽宁成大生物股份有限公司关于以集中竞价交易方式回购公司股份的进展公告 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，公司在回购股份期间，应当在每个月的前3个交易日内披露截至上月末的回购进展情况。公司回 购股份的进展情况如下： 2025年11月，公司未实施股份回购。截至2025年11月30日，公司通过上海证券交易所交易系统以集中竞 价交易方式已累计回购公司股份384,899股，占公司总股本的比例约为0.092%，回购成交的最高价为 29.61元/股，最低价为27.20元/股，已支付的资金总额为人民币10,789,216.56元（不含交易费用和佣 金）。 上述回购股份符合相关法律法规及公司回购股份方案的规定。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行 ...

证券代码：688739 证券简称：成大生物 公告编号：2025-056 辽宁成大生物股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上述回购股份符合相关法律法规及公司回购股份方案的规定。 | 回购方案首次披露日 | 2025/6/19 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 6 | 6 | 19 | 日~2026 | 年 | 月 | 18 | 日 | | 预计回购金额 | 万元~2,000 1,000 | | | 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 股 384,899 | | | | | | | | | 累计已回购股数占总股本 ...

Core Insights - The price war in the vaccine industry is driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [2][10][15] Group 1: Price Trends - The price of a three-valent flu vaccine has dropped to 5.5 yuan, lower than the price of a cup of milk tea, indicating a drastic reduction in vaccine prices [3][7] - The price of the four-valent flu vaccine has decreased from 128 yuan to 88 yuan, with further reductions expected as competition intensifies [7][8] - HPV vaccines have also seen significant price drops, with the two-valent HPV vaccine priced at 27.5 yuan, down over 90% from previous prices [8] Group 2: Industry Response - The China Vaccine Industry Association issued an initiative to combat "involutionary" competition, urging members to avoid bidding below cost and maintain price stability [4][5] - The association's initiative aims to stabilize price expectations but may not address the underlying issue of overcapacity in the industry [3][10] Group 3: Market Dynamics - The vaccine market is experiencing overcapacity due to an influx of companies entering the sector, leading to intense competition and price wars [10][11] - Demand for vaccines is under pressure, with declining public trust in vaccines and a decrease in birth rates affecting the market for childhood vaccines [11][12] Group 4: Financial Impact - Vaccine companies have reported significant financial losses, with overall revenue for listed vaccine companies dropping by 60% and net profits declining by 113% in the first half of 2025 [12][14] - Major companies like Zhifei Biological and Wantai Biological have reported substantial revenue declines and net losses, reflecting the severe impact of the price war [12][14] Group 5: Future Outlook - Experts suggest that the industry may need to undergo a period of consolidation and restructuring, which could last five to ten years, to address the current challenges [15] - Companies are exploring international markets and differentiation strategies to navigate the competitive landscape, with some reporting significant increases in exports [15]